Ypsomed’s Orbit infusion sets can be rotated 360°, giving users the freedom to move around, and are fitted using a heat-activated patch. The infusion sets are available with steel or soft cannulas, the company said, and Ypsomed plans to provide Bigfoot with an inserter for the company’s trial.
Bigfoot wrapped up the first clinical study of its automated insulin delivery system at the end of last year and hopes to start the pivotal trial next year.
“Both Ypsomed and Bigfoot Biomedical are dedicated to the development of products which simplify the everyday management of diabetes for those affected. Our partnership is an example of how consistently both companies follow this objective” Ypsomed CEO Simon Michel said in prepared remarks. “This cooperation gives us the opportunity of offering our popular Orbitinfusion sets to even more people with diabetes.”
“Ypsomed’s Orbit infusion set is thoughtfully designed,” Bigfoot president & CEO Jeffrey Brewer added. “We’re looking forward to incorporating a cannula and tubing that is flexible, reliable, and simple-to-operate into our clinical trial.”
In July, Bigfoot announced that it partnered with Abbott (NYSE:ABT) to bring together Abbott’s glucose monitoring tech and Bigfoot’s insulin delivery platform.
According to the deal, Abbott will provide Bigfoot with the next-gen version of its FreeStyle Libre continuous glucose monitor. The glucose monitor will be used to develop what the pair are touting as the first personalized system intended to optimize insulin delivery without the need for a fingerstick calibration.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.